Monthly Prescribing Reference1mon
REDEFINE 1 Trial: Superior Weight Loss Seen With CagriSema
CagriSema-treated patients achieved superior weight loss compared with those who received cagrilintide 2.4mg, semaglutide 2.4mg or placebo. Topline data were announced from a phase 3 trial ...
Reuters7d
Novo Nordisk will test CagriSema's long-term efficacy in late-stage trial, clinicaltrials.gov entry shows
LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy ...
Yahoo1mon
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
The company's latest attempt at a weight loss drug, CagriSema, matched the bar set by a currently approved medicine but still didn't surpass it. Since Ozempic blasted onto the stage in 2017 with ...
Nasdaq1mon
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual ...
Reuters7d
Novo Nordisk says it has not yet posted details about new CagriSema trial
Mexico's President Claudia Sheinbaum said on Sunday that reason should prevail a day after her government and the U.S. announced tariffs against one another, raising her fist in the air as she ...
Yahoo Finance1mon
Novo Nordisk stock price takes a tumble after the Wegovy maker’s next-generation weight-loss drug underwhelms
CagriSema, a drug that Novo Nordisk had hoped would become its next generation weight-loss aid, has failed to meet expectations in late-stage trials, sending shares of the pharmaceutical giant ...